Breaking World Pharma News
2nd Annual Next Generation Pharmaceutical Cleanrooms Conference
5 - 6 October 2022, London, United Kingdom.SAE Media Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Conference. An event that focuses on cleanroom technology in the pharmaceutical industry, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point.
Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries
Pfizer Inc. (NYSE: PFE) announced today an agreement to supply up to six million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) to Global Fund as part of its COVID-19 Response Mechanism (C19RM). The C19RM has been the primary channel for providing grant support to low- and middle-income countries to purchase COVID-19 tests, treatments, personal protective equipment and critical elements of health systems strengthening. Shutting down backup genes leads to cancer remission in mice
Their machine-learning algorithm can identify backup genes that only tumor cells are using so that drugs can target cancer precisely.
Bird's enzyme points toward novel therapies
The species of bird is the only one known to naturally produce an enzyme able to generate a noncanonical amino acid; that is, one not among the 20 necessary to encode most proteins.
WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking malaria vaccine. This is the first prequalification for a malaria vaccine and is an important step in rolling out the vaccine in countries with moderate to high P. falciparum malaria transmission. WHO strongly advises against antibody treatments for COVID-19 patients
These drugs work by binding to the SARS-CoV-2 spike protein, neutralising the virus's ability to infect cells.
Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Omicron BA.4/BA.5 15/15 µg) has been recommended for conditional marketing authorization (cMA) by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for individuals ages 12 years and older. Mucosal antibodies in the airways protect against omicron infection
Drug turns cancer gene into "eat me" flag for immune system
More Pharma News ...
Business & Industry
- Pfizer to supply Global Fund up to 6 million PAXLOVID™ treatment courses for low-and-middle-income countries
- WHO grants prequalification to GSK's Mosquirix - the first and only approved malaria vaccine
- Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster in European Union
- Novartis invests in early technical development capabilities for next-generation biotherapeutics
- FDA grants Breakthrough Therapy Designation to Pfizer's Group B Streptococcus vaccine candidate
Research & Development
- National CDC-funded study confirms that mRNA vaccines protect against serious COVID-19 during pregnancy
- 2nd Annual Next Generation Pharmaceutical Cleanrooms Conference
- Shutting down backup genes leads to cancer remission in mice
- Bird's enzyme points toward novel therapies
- WHO strongly advises against antibody treatments for COVID-19 patients
- Mucosal antibodies in the airways protect against omicron infection
- Drug turns cancer gene into "eat me" flag for immune system
Conferences & Events
- SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
- Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
- SMi's 22nd Annual Pain Therapeutics Conference
- SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
- SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
- SMi's 3rd Annual AI in Drug Discovery Conference
- SMi's 6th Annual Highly Potent Active Pharmaceutical Ingredients
Regulatory Affairs
- FDA approves first treatment for Acid Sphingomyelinase Deficiency, a rare genetic disease
- FDA approves first systemic treatment for alopecia areata
- FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
- FDA limits use of Janssen COVID-19 vaccine to certain individuals
- EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice